SPECIAL NOTICE
A -- Intent to Announce - Request for Prototype Proposals under Medical Countermeasure Systems Other Transaction Agreement
- Notice Date
- 6/1/2016
- Notice Type
- Special Notice
- NAICS
- 541330
— Engineering Services
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - NJ (W15QKN), BUILDING 10 PHIPPS RD, PICATINNY ARSENAL, New Jersey, 07806-5000, United States
- ZIP Code
- 07806-5000
- Solicitation Number
- W15QKN-16-Z-05SM
- Point of Contact
- Kristen Kachur, Phone: 9737243217
- E-Mail Address
-
kristen.e.kachur.civ@mail.mil
(kristen.e.kachur.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce two Request for Prototype Proposals (RPP1 & RPP2) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the National Chemical and Biological Defense Consortium, and industry in general, advanced notification of Government intent. On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the National Chemical and Biological Defense Consortium (NCBDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the NCBDC as a result of member project proposals submitted via the Request for Prototype Proposals process. The Government anticipates seven (7) projects to be solicited via W15QKN-16-9-1002-RPP1 & RPP2, consisting of the following: RPP1 1. Development of Monoclonal Antibody Medical Countermeasures against Aerosolized Botulinum Toxin Serotypes A and B 2. Fill/Finish of Venezuelan Equine Encephilits (VEE) virus like particles (VLP) Bulk Drug Product RPP2 1. Development of a Dual Drug Delivery Device (D4) 2. Lyophilized Formulation and Final Product Manufacturing Process for Western/Eastern/Venezuelan Equine Encephilitis (WEVEE) Vaccine 3. VEE Monovalent VLP Phase 1 Clinical Study 4. Eastern Equine Encephilitis Vaccine (EEEV) Prototypes 5. Definitive Efficacy Studies (2) of Pyridostigmine Bromide (PB) In order to obtain more information regarding the above projects, you must be a member of the National Chemical and Biological Defense Consortium (NCBDC), http://ncbdconsortium.org. For more information regarding membership or general questions to the NCBDC, contact Michael Stebbins, at 843-760-4094 or NCBD.consortium@scra.org.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/3f17ac7610acb94653016ddc6667b961)
- Record
- SN04134669-W 20160603/160601234837-3f17ac7610acb94653016ddc6667b961 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |